DSGN – design therapeutics, inc. (US:NASDAQ)

News

Design Therapeutics (NASDAQ:DSGN) was upgraded by analysts at Craig Hallum to a "strong-buy" rating.
Design Therapeutics (NASDAQ:DSGN) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
Design Therapeutics (NASDAQ:DSGN) is now covered by analysts at Craig Hallum. They set a "buy" rating on the stock.
Design Therapeutics (NASDAQ:DSGN) was given a new $14.00 price target on by analysts at Leerink Partners.
Design Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com